BI06 Short sharp shock or slow burn: clinician perspectives on treatment of actinic keratoses with 5-fluorouracil 5% cream monotherapy vs. 5-fluorouracil/calcipotriol ointment combination therapy

Abstract Actinic keratoses (AK) are common in immunocompromised patients and associated with increased risk of cutaneous squamous cell carcinoma (cSCC). The current standard care is 5-fluorouracil cream 5% (5-FU) monotherapy for 4 weeks. In recent years, 5-FU calcipotriol ointment (5-FU-Cal) combination AK therapy 4–6 days has emerged as potentially more effective better tolerated, although the original randomized controlled trial (RCT) excluded immunosuppressed patients. Previously, we shared patients’ real-world perspectives using vs. 5-FU-Cal (Junejo MH, Demirel S, Matin R et al. Short shock or slow burn? Patient on treatment actinic versus plus therapy. Clin Exp Dermatol 2023; 48:31–2). majority (81%) found to be than monotherapy. Despite 47% reporting worse local skin reactions (LSRs), most preferred combination. We now report results from a clinician survey use AK. An online was sent 200 UK consultant dermatologists. Fifty-seven (28.5%) completed survey, all whom reported treating prior cSCC; 43 (75%) this their treatment. Most clinicians (n = 40; 70%) were aware therapy, only 24 (42%) it treat cSCC. Of these, 18 used part field change, 14 (58%) patches five 13 (54%) grouped Very few 4; 17%) cSCC situ 4), single 3) superficial basal 1). 5-FU-Cal, felt that developed LSRs often 11; 46%) always 7; 29%); fewer occurred sometimes 5; 21%) rarely 1; 4%). Clinicians primarily moderate but not severe enough require supplementary discontinuation 17; 71%). Half 12; 50%) those did signal preference between Two-thirds 38/57; 67%) an interest participating RCT comparing sunscreen alone This first evaluation newly emerging These data provide rationale inclusion future studies topical treatments prevention UK.